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S U M M A R Y
Objectives: Hepatitis B virus (HBV), hepatitis C virus (HCV), and the human immunodeﬁciency virus
(HIV) are endemic in Africa. However, hepatitis co-infection rates among HIV-infected individuals
remain controversial. The aim of this review was to determine the prevalence of HBV and HCV in HIV-
infected patients in sub-Saharan Africa and to analyze whether HIV is associated with a higher HBV/HCV
prevalence in that region.
Design and methods: We performed a systematic review and meta-analysis. Studies reporting HBV and
HCV prevalence data amongst HIV-infected patients in sub-Saharan Africa were included. Weighted
means and medians across studies were calculated. Studies including an HIV-negative control group
were used for meta-analysis. Risk ratios (RRs) were calculated using a random effects model.
Results: Sixty studies were included. Among HIV-infected individuals, mean HBsAg and anti-HCV
prevalence rates were 15% and 7%, respectively. RRs for a positive HBsAg and a positive anti-HCV were
1.40 (95% conﬁdence interval (CI) 1.16–1.69) and 1.60 (95% CI 1.05–2.45) for HIV-infected, as compared
to HIV-uninfected, patients.
Conclusions: Many HIV-positive individuals in sub-Saharan Africa are HBV or HCV co-infected. HIV is
associated with a higher prevalence of both HBV and HCV in this region. However, this association is less
evident than that observed in Western countries and varies between studies.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Globally, an astounding number of people are infected with the
hepatitis B virus (HBV; 350 million), hepatitis C virus (HCV; 170
million), and human immunodeﬁciency virus (HIV; 33 million).
Africa has been hit hardest by the HIV pandemic and has the second
highest HBV and HCV prevalence, following Asia.1 Due to shared
routes of transmission, a frequent occurrence of HIV/hepatitis co-
infections seems likely. Indeed, inWestern countries the prevalence
of bothHBVandHCV is increased amongHIV-infected individuals.2–
4 However, modes and times of HBV and HCV transmission vary
between resource-rich and resource-limited countries. Western
prevalence data can therefore not be extrapolated to African
settings. Furthermore, the association between HIV and HBV/HCV
occurrence may be less prominent in African countries, as most
individuals experience HBV exposure long before acquiring HIV.
Due to increasing access to antiretroviral therapy (ART) in sub-
Saharan Africa, life expectancy for HIV-infected individuals has
improved dramatically. As people live longer, HBV- and HCV-* Corresponding author. Tel.: +31 621224407.
E-mail address: r.e.barth@umcutrecht.nl (R.E. Barth).
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become more prominent. There is evidence that HIV increases
the speed of HBV- and HCV-related liver disease, further
accentuating hepatic dysfunction in HIV-infected individuals.3,5,6
Moreover, as several antiretroviral drugs (ARVs) have dual anti-
HIV and anti-HBV activity, other treatment choices need to be
made in settings where HBV prevalence is high. Reliable
epidemiological data are needed in order to make estimations
on the logistical, economical, and humanitarian impact of hepatitis
co-infections in HIV-infected individuals in sub-Saharan Africa and
to guide future policy makers.
The aim of this review was to determine the prevalence of HBV
and HCV co-infections in HIV-infected patients in sub-Saharan
Africa. Furthermore, we aimed to clarify whether the prevalence of
these hepatitis viruses differs between HIV-infected and HIV-
uninfected individuals in that region.
2. Methods
2.1. Literature search
An English-language literature search was conducted using the
PubMed and Cochrane databases through October 1, 2009. Theses. Published by Elsevier Ltd. All rights reserved.
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or hepatitis C or HBV or HCV or HBV-DNA or HCV-DNA’’ AND
‘‘Africa or Afrika or Sub-Sahara Africa or Sub Sahara Africa or
Southern Africa’’ AND ‘‘HIV or AIDS or human immunodeﬁciency
virus or acquired immunodeﬁciency syndrome’’. Titles and/or
abstracts were screened to determine the relevance of the studies.
Full-texts of selected studies were reviewed.
2.2. Inclusion and exclusion criteria
Studies that reported HBV and/or HCV prevalence data of HIV-
infected adults in sub-Saharan Africa were selected for inclusion.
Publications including fewer than 20 HIV-infected individuals or
not including data on patients whowere infectedwith both HBV or
HCV and HIV were excluded. Pediatric studies, studies basing
patient selection on the presence of liver disease, studies from
outside sub-Saharan Africa, reporting in vitro data only, or without
original data were also excluded.
Studies reporting HBV/HCV prevalence data of an HIV-negative
control group were used for meta-analysis.
2.3. Data extraction and quality assessment
Full text articles were independently reviewed by two persons
(RB, QH) for the following criteria: (1) study design, (2) speciﬁc
study population characteristics, (3) serological evidence of HBV
(hepatitis B surface antigen (HBsAg), hepatitis B core antibody
(anti-HBc), and hepatitis B e antigen (HBeAg)) or HCV (hepatitis C
virus antibody (anti-HCV)) in HIV-infected (and possibly HIV-
uninfected) individuals, (4) absolute numbers of HBV/HCV-
infected patients that were provided, or could be calculated from
the available data.[(Figure_1)TD$FIG]Figure 1. Search strategy ﬂow chart2.4. Statistical analysis
Quantitative data on the number of subjects with serological
evidence for HBV and/or HCV infection were extracted, as well as
the number of included HIV-infected and HIV-uninfected (in some
studies) individuals. Medians across studies were calculated and,
because of great heterogeneity, presented with ranges of values. In
addition, weighted means were calculated, taking the different
study sizes into account. Proportions were compared with the Chi-
square test.
For the meta-analysis contingency tables were created to
compare HBsAg and anti-HCV prevalence data between HIV-
infected and HIV-uninfected subjects. Given the inherent variabil-
ity among observational studies, we used the random effects
model by DerSimonian and Laird to estimate summary risk ratios
(RRs) and 95% conﬁdence intervals (95% CIs) from included
studies.7 Heterogeneity across studies was assessed with the tau-
squared (t2) statistic; t2 > 0.1 suggests substantial heterogeneity.8
Estimations of publication bias were made by eyeballing funnel-
plots. MIX-for-meta-analysis software was used for analysis.9
3. Results
3.1. Study selection and study characteristics
The electronic search yielded 637 citations; on the basis of titles
and abstracts 502 publications were eliminated. After a full-text
review, another 75 were excluded. The remaining 60 studies were
included in the analysis (Figure 1, Table 1 10–69).
HBV prevalence data were described in 50 studies including a
total of 12 639 HIV-infected subjects. Thirty-ﬁve studies provided
HCV data for 9029 HIV-positive patients.and reasons for study exclusion.
Table 1
HBV and HCV in HIV-infected patients in sub-Saharan Africa
Design Cohort Female (%) Test HIV-pos (n) Prevalence (%) HIV-neg (n) Prevalence (%)
Botswana
200610 Co U 64 HBsAg 141 10.6 NA NA
Anti-HBc 58.2
Anti-HCV 50 0
Burkina Faso
200711 Co U, P 100 HBsAg 48 10.4 331 7.6
200612 Co U, P 100 HBsAg 207 11.6 129 7
Anti-HCV 4.8 6.2
200613 Co U, R, P, B 75 HBsAg 39 28.2 644 15.5
Anti-HCV 0 1.9
200514 CS U, P 100 Anti-HCV 58 12.1 489 2.2
200415 CS U, P 100 HBsAg 108 13.0 321 8.1
Cameroon
200716 CS R 53 Anti-HCV 35 8.6 441 22.0
200317 CS U, B 22 HBsAg 20 20.0 232 9.9
Anti-HCV 10.0 4.3
Central African Republic
199518 CS U 67 HBsAg 30 6.7 127 13.4
Anti-HCV 3.3 5.5
Democratic Republic of Congo
200119 CS U, P, S 100 Anti-HCV 421 7.4 1806 5.0
Cote d’Ivoire
200420 Co U, P 100 HBsAg 499 9.0 498 8.0
Anti-HCV 1.2 0.8
200121 CS U 100 HBsAg 199 10.6 206 9.7
Anti-HBc 82.7 81.1
Anti-HCV 2.5 3.4
199022 CS U, R, B 38 HBsAg 370 23.2 1457 9.3
Ethiopia
200823 CS U 53 HBsAg 305 3.9 315 5.4
Anti-HBc 47.5 41.9
200824 CS P 100 HBsAg 57 7.0 423 7.3
Anti-HCV 1.8 1.2
200825 CS U, B 90 HBsAg 27 14.8 573 7.9
Anti-HCV 22.2 5.1
200226 CS U NA Anti-HCV 165 4.5 2663 0.8
199727 Co U, B 0 HBsAg 83 12.0 466 14.8
Ghana
199928 CS U, R 44 HBsAg 182 16.5 88 11.4
Anti-HCV 8.2 4.5
Kenya
200829 Co U, H 45 HBsAg 378 6.1 NA NA
Anti-HCV 1.1
200530 Co U, B 12 HBsAg 478 11.5 8085 4.3
199031 CS U 41 HBsAg 41 12.2 NA NA
Anti-HBc 75.6
Malawi
200832 Co U, H 61 HBsAg 152 20.4 42 7.1
Anti-HCV 5.0 2.4
200233 CC R 0 HBsAg 279 16.9 280 14.4
Anti-HCV 12.7 10.0
199834 CC R, P 100 HBsAg 50 16.0 100 12.0
Anti-HBc 68.0 73.0
Anti-HCV 12.0 18.0
Mali
200935 CS U, B 13 HBsAg 518 25.3 11 074 14.4
Mozambique
200836 CS U 75 Anti-HCV 300 15.7 NA NA
200737 Co U, B 22 HBsAg 217 10.6 1361 9.0
Anti-HBc 69.6 62.5
Anti-HCV 1.4 1.5
Nigeria
200938 CS U 71 HBsAg 260 13.1 NA NA
Anti-HCV 3.8
200839 Co U 67 HBsAg 1779 11.9 NA NA
Anti-HCV 4.8
200740 Co U 65 Anti-HCV 1044 8.6 NA NA
200741 Co - 55 HBsAg 180 27.8 NA NA
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Table 1 (Continued )
Design Cohort Female (%) Test HIV-pos (n) Prevalence (%) HIV-neg (n) Prevalence (%)
Anti-HCV 18.3
200642 CC U, H 47 HBsAg 54 51.9 40 12.5
200643 Co U, H 49 HBsAg 300 70.3 NA NA
200544 Co U, B 49 HBsAg 490 25.9 175 14.3
200445 Co - 49 Anti-HCV 146 8.2 NA NA
200446 CS U, B NA HBsAg 383 9.7 5354 10.7
200447 Co U 44 HBsAg 342 9.7 NA NA
200248 CS U 39 HBsAg 106 31.1 594 4.5
Senegal
200849 Co U 55 HBsAg 363 16.8 NA NA
Anti-HBc 83.2
Anti-HCV 8.0
South Africa
200950 Co U 68 HBsAg 192 22.9 NA NA
Anti-HBc 38.0
200951 CS U NA HBsAg 502 4.8 NA NA
Anti-HBc 35.3
200852 Co - 6 HBsAg 537 19.7 NA NA
200853 CS R, H NA Anti-HCV 778 13.4 1159 1.7
200754 CC P 100 HBsAg 710 6.2 710 5.8
Anti-HBc 37.3 28.6
200655 CC U, H 50 HBsAg 167 16.2 128 35.2
Anti-HBc 85.0 82.0
Anti-HCV 1.9 5.1
200056 Co U, H 48 HBsAg 100 6.0 NA NA
Anti-HBc 41.0
Anti-HCV 1.0
199157 CC U, P 100 HBsAg 21 4.8 42 9.5
Anti-HBc 23.8 31.0
Tanzania
200858 CS U 70 HBsAg 260 17.3 NA NA
Anti-HCV 18.1
200659 CS U 100 HBsAg 338 4.5 44 4.1
Anti-HCV 2.3 0.9
200660 CS U, B 11 HBsAg 58 8.6 1495 8.7
Anti-HCV 0.0 1.6
200061 CS U, R 57 Anti-HCV 22 4.5 475 1.1
199962 Co R, P 100 HBsAg 66 9.1 914 6.1
Uganda
200963 CS U,R 55 HBsAg 378 8.3 5497 10.4
Anti-HBc 59.0 51.9
(+ Rwanda) 200764 Co P 100 HBsAg 247 4.1 NA NA
Anti-HCV 2.1
200265 CC U, R 61 HBsAg 129 17.8 129 13.1
Anti-HBc 65.1 41.9
(+ Burundi) 199066 CS R, P, H 43 HBsAg 90 11.1 358 11.2
Zaire
199467 CS U, P, B NA HBsAg 112 26.8 533 16.5
Anti-HBc 59.8 52.5
Zambia
199668 Co U, R, P 100 HBsAg 340 7.1 1524 5.4
Zimbabwe
200369 CS R 83 Anti-HCV 124 0.8 145 0.0
HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeﬁciency virus; n, number of patients; HIV-pos, number of HIV-infected individuals included in the study;
HIV-neg, number of HIV-uninfected patients included in the study; Co, cohort study; CS, cross-sectional study; CC, case–control study; U, urban population; R, rural
population; P, pregnantwomen; B, blood donors; S, commercial sexworkers; H, admitted patients; NA, not available; HBsAg, hepatitis B surface antigen; anti-HBc, hepatitis B
core antibody; anti-HCV, hepatitis C virus antibody.
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reporting HBsAg and 23 including anti-HCV test results were used
for the meta-analysis.
Studies from 20 different sub-Saharan African countries were
included. No trials or prospective studies were published; all were
either retrospective or cross-sectional. Most studies were set in
urban areas and women predominated. Study populations
frequently consisted of blood donors or pregnant women. In one
cohort sex-workers were included. Study characteristics are
summarized in Table 1.3.2. Prevalence of HBV and HCV in HIV-infected individuals
HBsAg prevalence data from 18 different countries were
available. Median reported HBsAg prevalence in HIV-infected
individuals across studies was 12.1% (range 3.9–70.3%). Results per
country are presented in Table 1 and in Figure 2. The weighted
mean prevalence was somewhat higher, at 14.9% (1879 out of 12
639 patients). Thirteen studies provided data on HBeAg prevalence
among patients who tested HBsAg-positive. Of the HIV/HBV co-
infected patients, 17.1% (82/480) were also HBeAg-positive. HBeAg
[(Figure_2)TD$FIG]
Figure 2. HBsAg prevalence rates in sub-Saharan African HIV-infected individuals per country.
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415; p = 0.5).
More than half of HIV-positive patients tested anti-HBc-
positive. The median across studies was 59.8% (range 23.8–
90.0%), whereas the weighted mean was 55.1% (2014 of 3658
patients).
Fewer people had been in contact with HCV; 620 of 9029 (6.9%)
tested HIV-infected people were anti-HCV-positive. The median
across studies was 4.8% (range 0.0–22.2%).
3.3. Meta-analysis
Studies that included an HIV-negative control group were
included in the meta-analysis. The RR for having a positive HBsAg
among HIV-infected patients compared with HIV-uninfected
patients was 1.40 (95% CI 1.16–1.69; Figure 3). Included studies
were heterogeneous. The t2 statistic was 0.2.
The RR for a positive anti-HCV amongHIV-positive as compared
to HIV-negative patients was 1.60 (95% CI 1.05–2.45; Figure 3).
Studies included in this analysis were evenmore heterogeneous as
is shown by the t2 statistic of 0.6. The funnel plots in both analyses
showed a symmetric distribution of studies (data not shown).
Therefore, publication bias did not seem likely.
4. Discussion
The 60 studies included in this review show that a considerable
number of HIV-infected patients in sub-Saharan Africa are HBV or
HCV co-infected. Mean HBsAg and anti-HCV prevalence rates were
15% and 7%, respectively. Furthermore, a meta-analysis was done
which showed a 40% increased risk for a positive HBsAg and a 60%increased risk for a positive anti-HCV in HIV-infected, as compared
to HIV-uninfected, patients.
In Western countries HIV infection is strongly associated with
an increased incidence of both HBV and HCV.2–4 This association is
attributed to shared routes of transmission: mostly (homo)sexual
contact in the case of HBV and intravenous drug use (IVDU) for
hepatitis C.70–72 In African countries HBV acquisition is assumed to
occur during early childhood. As the route of HIV transmission in
Africa is mainly via heterosexual contact, at a later point in life, it
can be expected that the association between both infections is
limited. However, reliable data on the mode and age of HBV
acquisition amongst HIV-infected individuals in Africa are lacking.
The predominant mode of HCV transmission in Africa has not yet
been established. However, IVDU appears to be less inﬂuential
than in Western countries.70–72 Due to the different times and
modes of transmission, the observed association between HIV and
the hepatic viruses is less evident in sub-Saharan Africa. Still, the
burden of HIV/hepatitis co-infections in that region is high, as all
these viruses are highly endemic. According to World Health
Organization (WHO) estimates, 22.5 million HIV-infected people
lived in sub-Saharan Africa by the end of 2007.73 When
geographical variations in HBV and HIV prevalence are not taken
into account, an HBsAg prevalence of 15% would mean that 3.4
million HBV/HIV co-infected people live in this region.
Deﬁning the proportion of HIV-infected people with active HBV
replication is more hazardous. We did not ﬁnd a signiﬁcant
difference in HBeAg positivity between HIV-infected and HIV-
uninfected individuals, but only a small sample of HBsAg-positive
people were tested for HBe antigenemia. Moreover, testing for
HBeAg is not the accurate way to establish the HBV replication
status when precore/core promoter mutations are present. Such
[(Figure_3)TD$FIG]
Figure 3. Forrest plots regarding the risk of a positive HBsAg and the risk of a positive anti-HCV in African HIV-infected compared to HIV-uninfected patients.
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compared to HBVmono-infected patients.74,75 In order to establish
the exact number of people harboring replicative HBV, molecular
HBV diagnostics are needed, but such diagnostics are generally not
feasible in sub-Saharan African countries for ﬁnancial and logistic
reasons.
HIV accelerates the progression of HBV- and HCV-related liver
disease. Evidence that such co-infections are also associated with
an increased mortality became available only recently.5,76 It is to
be expected that HBV- and HCV-related cirrhosis andmalignancies
will become even more evident during the coming years, as ART
roll-out carries on and life-expectancy for HIV-individuals
improves.Knowledge of a patient’s HBV/HCV status can help clinicians
interpret clinical problems and laboratory results. More important-
ly, such information can guide decisions on which ARVs can best be
prescribed in co-infected patients. The vastmajority of ﬁrst-lineART
regimens in sub-SaharanAfrica contain lamivudine. Lamivudine has
long been approved for the treatment of chronic HBV. However, it
has a poor resistance proﬁle. Around half of HBV isolates show drug
resistance mutations after 2–3 years of lamivudine use.77,78
Tenofovir is not yet widely available in sub-Saharan Africa, but its
usemay increaseduringcomingyears. Thisnucleotideanaloguewas
approved for the treatmentofHBV in2008.RatesofHBVsuppression
in mono-infected patients are impressive and the development of
drug resistance appears to be limited.79 Another problem regarding
R.E. Barth et al. / International Journal of Infectious Diseases 14 (2010) e1024–e1031e1030lamivudine use in HIV/HBV co-infected patients can arise when
lamivudine is being stopped. A paradoxical HBV ‘ﬂare up’ can occur,
potentially causing liver tissue destruction.80
Treating HCV infections is not feasible in most African settings
due to the high costs and intensive monitoring associated with
currently available therapies. Still, knowledge of a possible HCV co-
infection is useful. Screening policies for liver cirrhosis and
hepatocellular carcinomas can be installed and the use of
hepatotoxic agents can be minimized.
As always, prevention is better than cure. Patients who are
HBV- or HCV-infected should be informed about transmission
routes and methods to prevent further spread of the viruses.
Furthermore, patients who test HBV-negative and have not yet
been vaccinated should still receive a vaccine in order to prevent
future infection. For HCV, such a strategy is unfortunately not
possible, as a vaccine does not exist.
Our study has potential limitations. First, due to the observa-
tional nature of included studies and heterogeneity between
studies, the validity of included data may be weakened. It can
therefore be questioned if calculating a single prevalence rate for
such a large and diverse region is useful. For individual treatment
decisions it is indeed important to take local epidemiological data
into account. However, we feel that pooling data is relevant, as it
gives an insight into the magnitude of the hepatitis/HIV co-
infection problem in sub-Saharan Africa. Second, as most studies
were set in urban areas and as females predominated in included
studies, the generalizability of these data may be somewhat
compromised. Third, inmost studies, and therefore in our review, a
positive HBsAg is used as a surrogate marker for an HBV infection.
As a result, occult hepatitis B infections (positive HBV DNA in the
absence of a positive HBsAg) are overlooked. Even though the
prevalence and clinical relevance of occult HBV in HIV-positive
subjects remain controversial,81 the true prevalence of HBVmay be
underestimated. In contrast to HBV, a distinction between active
and spontaneously resolved infections cannot be made solely on
the basis of serology for HCV. The actual HCV prevalence may
therefore be lower than presented here. Last, although we used a
wide search strategy, data presented solely at conferences or in
regional journals may have been overlooked.
In conclusion, many HIV-positive individuals in sub-Saharan
Africa are HBV or HCV co-infected. HIV is associated with a higher
prevalence of both HBV and HCV in this region. This association is
nevertheless less evident than in Western countries and varies
between studies. Local epidemiological data regarding the
distribution of the viruses are needed to guide future policies on
HBV, HCV and HIV treatment and prevention strategies.
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